行情

CLSN

CLSN

Celsion
NASDAQ

实时行情|Nasdaq Last Sale

1.240
-0.200
-13.89%
已收盘, 16:00 11/11 EST
开盘
1.430
昨收
1.440
最高
1.430
最低
1.200
成交量
25.31万
成交额
--
52周最高
2.630
52周最低
1.190
市值
2,652.04万
市盈率(TTM)
-3.3751
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CLSN 新闻

  • If You Had Bought Celsion (NASDAQ:CLSN) Stock Five Years Ago, You'd Be Sitting On A 96% Loss, Today
  • Simply Wall St..2天前
  • Celsion -4.9% amid holder filing to offer 4.5M shares
  • Seeking Alpha - Article.3天前
  • Celsion Corporation to Hold Third Quarter 2019 Financial Results Conference Call on Friday, November 15, 2019
  • GlobeNewswire.3天前
  • Celsion Announces DSMB Recommendation to Continue GEN-1 at 100mg/m² Dose to Complete the Phase I Portion of OVATION 2 Study in Ovarian Cancer
  • GlobeNewswire.6天前

更多

所属板块

生物技术和医学研究
-0.51%
制药与医学研究
-0.43%

热门股票

名称
价格
涨跌幅

CLSN 简况

Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).
展开

Webull提供Celsion Corporation的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。